|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu Y, Shao A, Wang L, Hu K, Yu C, Pan C
and Zhang S: The role of lncRNAs in the distant metastasis of
breast cancer. Front Oncol. 9:4072019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Spill F, Reynolds DS, Kamm RD and Zaman
MH: Impact of the physical microenvironment on tumor progression
and metastasis. Curr Opin Biotechnol. 40:41–48. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wan L, Pantel K and Kang Y: Tumor
metastasis: Moving new biological insights into the clinic. Nat
Med. 19:1450–1464. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kozłowski J, Kozłowska A and Kocki J:
Breast cancer metastasis-insight into selected molecular mechanisms
of the phenomenon. Postepy Hig Med Dosw (Online). 69:447–451. 2014.
View Article : Google Scholar
|
|
7
|
Bray SJ: Notch signalling in context. Nat
Rev Mol Cell Biol. 17:722–735. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bray SJ: Notch signalling: A simple
pathway becomes complex. Nat Rev Mol Cell Biol. 7:678–689. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brou C, Logeat F, Gupta N, Bessia C,
LeBail O, Doedens JR, Cumano A, Roux P, Black RA and Israël A: A
novel proteolytic cleavage involved in Notch signaling: The role of
the disintegrin-metalloprotease TACE. Mol Cell. 5:207–216. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sprinzak D, Lakhanpal A, Lebon L, Santat
LA, Fontes ME, Anderson GA, Garcia-Ojalvo J and Elowitz MB:
Cis-interactions between Notch and Delta generate mutually
exclusive signalling states. Nature. 465:86–90. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu L, Aster JC, Blacklow SC, Lake R,
Artavanis-Tsakonas S and Griffin JD: MAML1, a human homologue of
Drosophila mastermind, is a transcriptional co-activator for
NOTCH receptors. Nat Genet. 26:484–489. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
D'Souza B, Miyamoto A and Weinmaster G:
The many facets of Notch ligands. Oncogene. 27:5148–5167. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Visan I: Asymmetric division. Nature
Immunol. 13:1202012. View Article : Google Scholar
|
|
14
|
Santoro A, Vlachou T, Carminati M, Pelicci
PG and Mapelli M: Molecular mechanisms of asymmetric divisions in
mammary stem cells. EMBO Rep. 17:1700–1720. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bouras T, Pal B, Vaillant F, Harburg G,
Asselin-Labat ML, Oakes SR, Lindeman GJ and Visvader JE: Notch
signaling regulates mammary stem cell function and luminal
cell-fate commitment. Cell Stem Cell. 3:429–441. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dontu G, Jackson KW, Mcnicholas E,
Kawamura MJ, Abdallah WM and Wicha MS: Role of Notch signaling in
cell-fate determination of human mammary stem/progenitor cells.
Breast Cancer Res. 6:R605–R615. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rhyu MS, Jan LY and Jan YN: Asymmetric
distribution of numb protein during division of the sensory organ
precursor cell confers distinct fates to daughter cells. Cell.
76:477–491. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McGill MA and McGlade CJ: Mammalian numb
proteins promote Notch1 receptor ubiquitination and degradation of
the Notch1 intracellular domain. J Biol Chem. 278:23196–23203.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Honeth G, Bendahl PO, Ringnér M, Saal LH,
Gruvberger-Saal SK, Lövgren K, Grabau D, Fernö M, Borg A and
Hegardt C: The CD44+/CD24-phenotype is enriched in
basal-like breast tumors. Breast Cancer Res. 10:R532008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Calaf GM, Ponce-Cusi R and Abarca-Quinones
J: Effect of curcumin on the cell surface markers CD44 and CD24 in
breast cancer. Oncol Rep. 39:2741–2748. 2018.PubMed/NCBI
|
|
21
|
Huiping L, Patel MR, Prescher JA,
Patsialou A, Qian D, Lin J, Wen S, Chang YF, Bachmann MH, Shimono
Y, et al: Cancer stem cells from human breast tumors are involved
in spontaneous metastases in orthotopic mouse models. Proc Natl
Acad Sci USA. 107:18115–18120. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shipitsin M, Campbell LL, Argani P,
Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T,
Serebryiskaya T, Beroukhim R, Hu M, et al: Molecular definition of
breast tumor heterogeneity. Cancer Cell. 11:259–273. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Azzam DJ, Zhao D, Sun J, Minn AJ,
Ranganathan P, Drews-Elger K, Han X, Picon-Ruiz M, Gilbert CA,
Wander SA, et al: Triple negative breast cancer initiating cell
subsets differ in functional and molecular characteristics and in
γ-secretase inhibitor drug responses. EMBO Mol Med. 5:1502–1522.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chakrabarti R, Wei Y, Romano RA, DeCoste
C, Kang Y and Sinha S: Elf5 regulates mammary gland stem/progenitor
cell fate by influencing notch signaling. Stem Cells. 30:1496–1508.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li L, Guturi KKN, Gautreau B, Patel PS,
Saad A, Morii M, Mateo F, Palomero L, Barbour H, Gomez A, et al:
Ubiquitin ligase RNF8 suppresses Notch signaling to regulate
mammary development and tumorigenesis. J Clin Invest.
128:4525–4542. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kouros-Mehr H, Bechis SK, Slorach EM,
Littlepage LE, Egeblad M, Ewald AJ, Pai SY, Ho IC and Werb Z:
GATA-3 links tumor differentiation and dissemination in a luminal
breast cancer model. Cancer Cell. 13:141–152. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chakrabarti R, Hwang J, Andres Blanco M,
Wei Y, Lukačišin M, Romano RA, Smalley K, Liu S, Yang Q, Ibrahim T,
et al: Elf5 inhibits epithelial mesenchymal transition in mammary
gland development and breast cancer metastasis by transcriptionally
repressing Snail2. Nat Cell Biol. 14:1212–1222. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin HY, Liang YK, Dou XW, Chen CF, Wei XL,
Zeng, Bai JW, Guo YX, Lin FF, Huang WH, et al: Notch3 inhibits
epithelial-mesenchymal transition in breast cancer via a novel
mechanism, upregulation of GATA-3 expression. Oncogenesis.
7:592018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mack GS and Marshall A: Lost in migration.
Nat Biotechnol. 28:214–229. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu X, Li J, Cadilha BL, Markota A, Voigt
C, Huang Z, Lin PP, Wang DD, Dai J, Kranz G, et al: Epithelial-type
systemic breast carcinoma cells with a restricted mesenchymal
transition are a major source of metastasis. Sci Adv.
5:eaav42752019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shao S and Zhao X, Zhang X, Luo M, Zuo X,
Huang S, Wang Y, Gu S and Zhao X: Notch1 signaling regulates the
epithelial-mesenchymal transition and invasion of breast cancer in
a Slug-dependent manner. Mol Cancer. 14:282015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Leong KG, Niessen K, Kulic I, Raouf A,
Eaves C, Pollet I and Karsan A: Jagged1-mediated Notch activation
induces epithelial-to-mesenchymal transition through Slug-induced
repression of E-cadherin. J Exp Med. 204:2935–2948. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen J, Imanaka N, Chen J and Griffin JD:
Hypoxia potentiates Notch signaling in breast cancer leading to
decreased E-cadherin expression and increased cell migration and
invasion. Br J Cancer. 102:351–360. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jian J, Yang Q, Shao Y, Axelrod D, Smith
J, Singh B, Krauter S, Chiriboga L, Yang Z, Li J and Huang X: A
link between premenopausal iron deficiency and breast cancer
malignancy. BMC Cancer. 13:3072013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu L, Chen X, Wang Y, Qu Z, Lu Q, Zhao J,
Yan X, Zhang H and Zhou Y: Notch3 is important for TGF-β-induced
epithelial-mesenchymal transition in non-small cell lung cancer
bone metastasis by regulating ZEB-1. Cancer Gene Ther. 21:364–372.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bolos V, Mira E, Martinez-Poveda B, Luxán
G, Cañamero M, Martínez-A C, Mañes S and de la Pompa JL: Notch
activation stimulates migration of breast cancer cells and promotes
tumor growth. Breast Cancer Res. 15:R542013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Brabletz S, Bajdak K, Meidhof S, Burk U,
Niedermann G, Firat E, Wellner U, Dimmler A, Faller G, Schubert J
and Brabletz T: The ZEB1/miR-200 feedback loop controls Notch
signalling in cancer cells. EMBO J. 30:770–782. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang X and Zhao X, Shao S, Zuo X, Ning Q,
Luo M, Gu S and Zhao X: Notch1 induces epithelial-mesenchymal
transition and the cancer stem cell phenotype in breast cancer
cells and STAT3 plays a key role. Int J Oncol. 46:1141–1148. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kim RK, Kaushik N, Suh Y, Yoo KC, Cui YH,
Kim MJ, Lee HJ, Kim IG and Lee SJ: Radiation driven
epithelial-mesenchymal transition is mediated by Notch signaling in
breast cancer. Oncotarget. 7:53430–53442. 2016.PubMed/NCBI
|
|
40
|
Jin S, Mutvei AP, Chivukula IV, Andersson
ER, Ramsköld D, Sandberg R, Lee KL, Kronqvist P, Mamaeva V, Ostling
P, et al: Non-canonical Notch signaling activates IL-6/JAK/STAT
signaling in breast tumor cells and is controlled by p53 and
IKKα/IKKβ. Oncogene. 32:4892–4902. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang J, Shao X, Sun H, Liu K, Ding Z,
Chen J, Fang L, Su W, Hong Y and Li H and Li H: NUMB negatively
regulates the epithelial-mesenchymal transition of triple-negative
breast cancer by antagonizing Notch signaling. Oncotarget.
7:61036–61053. 2016.PubMed/NCBI
|
|
42
|
Garcia-Heredia JM, Verdugo Sivianes EM,
Lucena-Cacace A, Molina-Pinelo S and Carnero A: Numb-like (NumbL)
downregulation increases tumorigenicity, cancer stem cell-like
properties and resistance to chemotherapy. Oncotarget.
7:63611–63628. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang J, Fu L, Gu F and Ma Y: Notch1 is
involved in migration and invasion of human breast cancer cells.
Oncol Rep. 26:1295–1303. 2011.PubMed/NCBI
|
|
44
|
Dou XW, Liang YK, Lin HY, Wei XL, Zhang
YQ, Bai JW, Chen CF, Chen M, Du CW, Li YC, et al: Notch3 maintains
luminal phenotype and suppresses tumorigenesis and metastasis of
breast cancer via trans-activating estrogen receptor-alpha.
Theranostics. 7:4041–4056. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Li L, Zhao F, Lu J, Li T, Yang H, Wu C and
Liu Y: Notch-1 signaling promotes the malignant features of human
breast cancer through NF-κB activation. PLoS One. 9:e959122014.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mahmood N, Mihalcioiu C and Rabbani SA:
Multifaceted role of the urokinase-type plasminogen activator (uPA)
and its receptor (uPAR): Diagnostic, Prognostic, and therapeutic
applications. Front Oncol. 8:242018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Heiss MM, Allgayer H, Gruetzner KU, Funke
I, Babic R, Jauch KW and Schildberg FW: Individual development and
uPA-receptor expression of disseminated tumour cells in bone
marrow: A reference to early systemic disease in solid cancer. Nat
Med. 1:1035–1039. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Shimizu M, Cohen B, Goldvasser P, Berman
H, Virtanen C and Reedijk M: Plasminogen activator uPA is a direct
transcriptional target of the JAG1-Notch receptor signaling pathway
in breast cancer. Cancer Res. 71:277–286. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Song J: Notch signaling mediates Tumor-CAF
crosstalk in basal-like breast cancer. 2014.
|
|
51
|
Liu ZJ, Lsemenza G and Zhang HF:
Hypoxia-inducible factor 1 and breast cancer metastasis. J Zhejiang
Univ Sci B. 16:32–43. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gupta GP and Massagué J: Cancer
metastasis: Building a framework. Cell. 127:679–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Semenza GL: HIF-1 and tumor progression:
Pathophysiology and therapeutics. Trends Mol Med. 8 (Suppl
4):S62–S67. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Harris AL: Hypoxia-a key regulatory factor
in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
De EF, Maggiolini M and Musti AM:
Crosstalk between Notch, HIF-1α and GPER in Breast Cancer EMT. Int
J Mol Sci. 19:20112018. View Article : Google Scholar
|
|
56
|
Lim SO, Kim HS, Quan X, Ahn SM, Kim H,
Hsieh D, Seong JK and Jung G: Notch1 binds and induces degradation
of Snail in hepatocellular carcinoma. BMC Biol. 9:832011.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Boufraqech M, Zhang L, Nilubol N, Sadowski
SM, Kotian S, Quezado M and Kebebew E: Lysyl Oxidase (LOX)
Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in
Human Cancers. Clin Cancer Res. 22:4491–4504. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Sahlgren C, Gustafsson MV, Jin S,
Poellinger L and Lendahl U: Notch signaling mediates
hypoxia-induced tumor cell migration and invasion. Proc Natl Acad
Sci USA. 105:6392–6397. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Villanueva MT: Metastasis: LOX does some
prepping. Nat Rev Cancer. 15:3842015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Deshmukh SK, Srivastava SK, Tyagi N, Ahmad
A, Singh AP, Ghadhban AAL, Dyess DL, Carter JE, Dugger K and Singh
S: Emerging evidence for the role of differential tumor
microenvironment in breast cancer racial disparity: A closer look
at the surroundings. Carcinogenesis. 38:757–765. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Aboussekhra A: Role of cancer-associated
fibroblasts in breast cancer development and prognosis. Int J Dev
Biol. 55:841–849. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Shimoda M, Principe S, Jackson HW, Luga V,
Fang H, Molyneux SD, Shao YW, Aiken A, Waterhouse PD, Karamboulas
C, et al: Loss of the Timp gene family is sufficient for the
acquisition of the CAF-like cell state. Nat Cell Biol. 16:889–901.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Procopio MG, Laszlo C, Al Labban D, Kim
DE, Bordignon P, Jo SH, Goruppi S, Menietti E, Ostano P, Ala U, et
al: Combined CSL and p53 downregulation promotes cancer-associated
fibroblast activation. Nat Cell Biol. 17:1193–1204. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Gajewski TF, Schreiber H and Fu YX: Innate
and adaptive immune cells in the tumor microenvironment. Nat
Immunol. 14:1014–1022. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Cho OH, Shin HM, Miele L, Golde TE, Fauq
A, Minter LM and Osborne BA: Notch regulates cytolytic effector
function in CD8+ T cells. J Immunol. 182:3380–3389. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Qiu H, Zmina PM, Huang AY, Askew D and
Bedogni B: Inhibiting Notch1 enhances immunotherapy efficacy in
melanoma by preventing Notch1 dependent immune suppressive
properties. Cancer Lett. 434:144–151. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Sugimoto K, Maekawa Y, Kitamura A, Nishida
J, Koyanagi A, Yagita H, Kojima H, Chiba S, Shimada M and Yasutomo
K: Notch2 signaling is required for potent antitumor immunity in
vivo. J Immunol. 184:4673–4678. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Palaga T, Wongchana W and Kueanjinda P:
Notch signaling in macrophages in the context of cancer immunity.
Front Immunol. 9:6522018. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Franklin RA, Liao W, Sarkar A, Kim MV,
Bivona MR, Liu K, Pamer EG and Li MO: The cellular and molecular
origin of tumor-associated macrophages. Science. 344:921–925. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Zhao JL, Huang F, He F, Gao CC, Liang SQ,
Ma PF, Dong GY, Han H and Qin HY: Forced activation of notch in
macrophages represses tumor growth by upregulating miR-125a and
disabling tumor-associated macrophages. Cancer Res. 76:1403–1415.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Hanahan D and Folkman J: Patterns and
emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Zhou Z, Yao H and Hu H: Disrupting Tumor
Angiogenesis and ‘the Hunger Games’ for Breast Cancer. Adv Exp Med
Biol. 1026:1712017. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Zetter BR: Angiogenesis and tumor
metastasis. Annu Rev Med. 49:407–424. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Cuervo H, Nielsen CM, Simonetto DA,
Ferrell L, Shah VH and Wang RA: Endothelial notch signaling is
essential to prevent hepatic vascular malformations in mice.
Hepatology. 64:1302–1316. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Kontomanolis EN, Kalagasidou S, Pouliliou
S, Anthoulaki X, Georgiou N, Papamanolis V and Fasoulakis ZN: The
notch pathway in breast cancer progression. ScientificWorldJournal.
2018:24154892018. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Blanco R and Gerhardt H: VEGF and Notch in
tip and stalk cell selection. Cold Spring Harb Perspect Med.
3:a0065692013. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Siekmann AF, Covassin L and Lawson ND:
Modulation of VEGF signalling output by the Notch pathway.
Bioessays. 30:303–313. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Mailhos C, Modlich U, Lewis J, Harris A,
Bicknell R and Ish-Horowicz D: Delta4, an endothelial specific
notch ligand expressed at sites of physiological and tumor
angiogenesis. Differentiation. 69:135–144. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Hellstrom M, Phng LK, Hofmann JJ, Wallgard
E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N,
et al: Dll4 signalling through Notch1 regulates formation of tip
cells during angiogenesis. Nature. 445:776–780. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Suchting S and Eichmann A: Jagged gives
endothelial tip cells an edge. Cell. 137:988–990. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Phng LK and Gerhardt H: Angiogenesis: A
team effort coordinated by notch. Dev Cell. 16:196–208. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Oon CE, Li JL, Sainson R, Sheldon H,
Turley H, Leek R and Harris A: 360 Role of DLL4 and JAG1 in tumour
angiogenesis. EJC Supplements. 8:92. 2010. View Article : Google Scholar
|
|
83
|
Panin VM, Papayannopoulos V, Wilson R and
Irvine KD: Fringe modulates Notch-ligand interactions. Nature.
387:908–912. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
84
|
Boareto M, Jolly MK, Ben-Jacob E and
Onuchic JN: Jagged mediates differences in normal and tumor
angiogenesis by affecting tip-stalk fate decision. Proc Natl Acad
Sci USA. 112:E3836–E3844. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Benedito R, Roca C, Sörensen I, Adams S,
Gossler A, Fruttiger M and Adams RH: The Notch Ligands Dll4 and
Jagged1 have opposing effects on Angiogenesis. Cell. 137:1124–1135.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Chen JY, Li CF, Chu PY, Lai YS, Chen CH,
Jiang SS, Hou MF and Hung WC: Lysine demethylase 2A promotes
stemness and angiogenesis of breast cancer by upregulating Jagged1.
Oncotarget. 7:27689–27710. 2016.PubMed/NCBI
|
|
87
|
Rodriguez-Vita J and Fischer A: Notch
signaling facilitates crossing of endothelial barriers by tumor
cells. Mol Cell Oncol. 4:e13118282017. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
White DE and Muller WJ: Multifaceted Roles
of integrins in breast cancer metastasis. J Mammary Gland Biol
Neoplasia. 12:135–142. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Deford P, Brown K, Richards RL, King A,
Newburn K, Westover K and Albig AR: MAGP2 controls Notch via
interactions with RGD binding integrins: Identification of a novel
ECM-integrin-Notch signaling axis. Exp Cell Res. 341:84–91. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Hodkinson PS, Elliott PA, Lad Y, McHugh
BJ, MacKinnon AC, Haslett C and Sethi T: Mammalian NOTCH-1
activates beta1 integrins via the small GTPase R-Ras. J Biol Chem.
282:28991–29001. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Liu B, Zheng X, Meng F, Han Y, Song Y, Liu
F, Li S, Zhang L, Gu F, Zhang X and Fu L: Overexpression of β1
integrin contributes to polarity reversal and a poor prognosis of
breast invasive micropapillary carcinoma. Oncotarget. 9:4338–4353.
2017.PubMed/NCBI
|
|
92
|
Stoletov K, Kato H, Zardouzian E, Kelber
J, Yang J, Shattil S and Klemke R: Visualizing extravasation
dynamics of metastatic tumor cells. J Cell Sci. 123:2332–2341.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Guo P and Rafii S: Dangerous liaisons:
Deviant endothelium NOTCHes toward tumor metastasis. Cancer Cell.
31:301–303. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Lianidou ES and Markou A: Circulating
tumor cells in breast cancer: Detection systems, molecular
characterization, and future challenges. Clin Chem. 57:1242–1255.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Boral D, Vishnoi M, Liu HN, Yin W, Sprouse
ML, Scamardo A, Hong DS, Tan TZ, Thiery JP, Chang JC and Marchetti
D: Molecular characterization of breast cancer CTCs associated with
brain metastasis. Nat Commun. 8:1962017. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Portanova P, Notaro A, Pellerito O,
Sabella S, Giuliano M and Calvaruso G: Notch inhibition restores
TRAIL-mediated apoptosis via AP1-dependent upregulation of DR4 and
DR5 TRAIL receptors in MDA-MB-231 breast cancer cells. Int J Oncol.
43:121–130. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Day TW, Huang S and Safa AR: c-FLIP
knockdown induces ligand-independent DR5-, FADD-, caspase-8-, and
caspase-9-dependent apoptosis in breast cancer cells. Biochem
Pharmacol. 76:1694–1704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Kim JW, Kim MJ, Kim KJ, Yun HJ, Chae JS,
Hwang SG, Chang TS, Park HS, Lee KW, Han PL, et al: Notch
interferes with the scaffold function of JNK-interacting protein 1
to inhibit the JNK signaling pathway. Proc Natl Acad Sci USA.
102:14308–14313. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Archibald A, Mihai C, Macara IG and
McCaffrey L: Oncogenic suppression of apoptosis uncovers a Rac1/JNK
proliferation pathway activated by loss of Par3. Oncogene.
34:3199–3206. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Zou W, Liu X, Yue P, Zhou Z, Sporn MB,
Lotan R, Khuri FR and Sun SY: c-Jun NH2-terminal kinase-mediated
up-regulation of death receptor 5 contributes to induction of
apoptosis by the novel synthetic triterpenoid
methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung
cancer cells. Cancer Res. 64:7570–7578. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Naik S, MacFarlane M and Sarin A: Notch4
signaling confers susceptibility to TRAIL-Induced Apoptosis in
breast cancer cells. J Cell Biochem. 116:1371–1380. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Phipps LE, Hino S and Muschel RJ:
Targeting cell spreading: A method of sensitizing metastatic tumor
cells to TRAIL-induced apoptosis. Mol Cancer Res. 9:249–258. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Meurette O, Stylianou S, Rock R, Collu GM,
Gilmore AP and Brennan K: Notch activation induces Akt signaling
via an autocrine loop to prevent apoptosis in breast epithelial
cells. Cancer Res. 69:5015–5022. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Tao L, Roberts AL, Dunphy KA, Bigelow C,
Yan H and Jerry DJ: Repression of mammary stem/progenitor cells by
p53 is mediated by Notch and separable from apoptotic activity.
Stem Cells. 29:119–127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Su F, Zhu S, Ruan J, Muftuoglu Y, Zhang L
and Yuan Q: Combination therapy of RY10-4 with the gamma-secretase
inhibitor DAPT shows promise in treating HER2-amplified breast
cancer. Oncotarget. 7:4142–4154. 2016.PubMed/NCBI
|
|
106
|
Hay N: The Akt-mTOR tango and its
relevance to cancer. Cancer Cell. 8:179–183. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Li L, Zhang J, Xiong N, Li S, Chen Y, Yang
H, Wu C, Zeng H and Liu Y: Notch-1 signaling activates NF-κB in
human breast carcinoma MDA-MB-231 cells via PP2A-dependent AKT
pathway. Med Oncol. 33:332016. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Guerrero-Zotano A, Mayer IA and Arteaga
CL: PI3K/AKT/mTOR: Role in breast cancer progression, drug
resistance, and treatment. Cancer Metastasis Rev. 35:515–524. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Mungamuri SK, Yang X, Thor AD and
Somasundaram K: Survival signaling by Notch1: Mammalian target of
rapamycin (mTOR)-dependent inhibition of p53. Cancer Res.
66:4715–4724. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Dotto GP: Crosstalk of Notch with p53 and
p63 in cancer growth control. Nat Rev Cancer. 9:587–595. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Kim SB, Chae GW, Lee J, Park J, Tak H,
Chung JH, Park TG, Ahn JK and Joe CO: Activated Notch1 interacts
with p53 to inhibit its phosphorylation and transactivation. Cell
Death Differ. 14:982–991. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Cherdyntseva NV, Litviakov NV, Denisov EV,
Gervas PA and Cherdyntsev ES: Circulating tumor cells in breast
cancer: Functional heterogeneity, pathogenetic and clinical
aspects. Exp Oncol. 39:2–11. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Zhang P, He D, Chen Z, Pan Q, Du F, Zang
X, Wang Y, Tang C, Li H, Lu H, et al: Chemotherapy enhances tumor
vascularization via Notch signaling-mediated formation of
tumor-derived endothelium in breast cancer. Biochem Pharmacol.
118:18–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Simões BM, O'Brien CS, Eyre R, Silva A, Yu
L, Sarmiento-Castro A, Alférez DG, Spence K, Santiago-Gómez A,
Chemi F, et al: Anti-estrogen resistance in human breast tumors is
driven by JAG1-NOTCH4-Dependent cancer stem cell activity. Cell
Rep. 12:1968–1977. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Sansone P, Ceccarelli C, Berishaj M, Chang
Q, Rajasekhar VK, Perna F, Bowman RL, Vidone M, Daly L, Nnoli J, et
al: Self-renewal of CD133(hi) cells by IL6/Notch3 signalling
regulates endocrine resistance in metastatic breast cancer. Nat
Commun. 7:104422016. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Boelens MC, Wu TJ, Nabet BY, Xu B, Qiu Y,
Yoon T, Azzam DJ, Twyman-Saint Victor C, Wiemann BZ, Ishwaran H, et
al: Exosome transfer from stromal to breast cancer cells regulates
therapy resistance pathways. Cell. 159:499–513. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Arteaga CL and Engelman JA: ERBB
receptors: From oncogene discovery to basic science to
mechanism-based cancer therapeutics. Cancer Cell. 25:282–303. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Jordan NV, Bardia A, Wittner BS, Benes C,
Ligorio M, Zheng Y, Yu M, Sundaresan TK, Licausi JA, Desai R, et
al: HER2 expression identifies dynamic functional states within
circulating breast cancer cells. Nature. 537:102–106. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Kang Y: Dissecting Tumor-Stromal
interactions in breast cancer bone metastasis. Endocrinol Metab
(Seoul). 31:206–212. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Zhang Z, Wang H, Ikeda S, Fahey F,
Bielenberg D, Smits P and Hauschka PV: Notch3 in human breast
cancer cell lines regulates osteoblast-cancer cell interactions and
osteolytic bone metastasis. Am J Pathol. 177:1459–1469. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Sethi N, Dai X, Winter CG and Kang Y:
Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast
cancer by engaging notch signaling in bone cells. Cancer Cell.
19:192–205. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Lee JH and Welch DR: Suppression of
metastasis in human breast carcinoma MDA-MB-435 cells after
transfection with the metastasis suppressor gene, KiSS-1. Cancer
Res. 57:2384–2387. 1997.PubMed/NCBI
|
|
123
|
Ohtaki T, Shintani Y, Honda S, Matsumoto
H, Hori A, Kanehashi K, Terao Y, Kumano S, Takatsu Y, Masuda Y, et
al: Metastasis suppressor gene KiSS-1 encodes peptide ligand of a
G-protein-coupled receptor. Nature. 411:613–617. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Leone A, Flatow U, Vanhoutte K and Steeg
PS: Transfection of human nm23-H1 into the human MDA-MB-435 breast
carcinoma cell line: Effects on tumor metastatic potential,
colonization and enzymatic activity. Oncogene. 8:2325–2333.
1993.PubMed/NCBI
|
|
125
|
Yu HG, Huang JA, Yang YN, Huang H, Luo HS,
Yu JP, Meier JJ, Schrader H, Bastian A, Schmidt WE and Schmitz F:
The effects of acetylsalicylic acid on proliferation, apoptosis,
and invasion of cyclooxygenase-2 negative colon cancer cells. Eur J
Clin Invest. 32:838–846. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Moon CM, Kwon JH, Kim JS, Oh SH, Jin Lee
K, Park JJ, Pil Hong S, Cheon JH, Kim TI and Kim WH: Nonsteroidal
anti-inflammatory drugs suppress cancer stem cells via inhibiting
PTGS2 (cyclooxygenase 2) and NOTCH/HES1 and activating PPARG in
colorectal cancer. Int J Cancer. 134:519–529. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Ignesti M, Barraco M, Nallamothu G,
Woolworth JA, Duchi S, Gargiulo G, Cavaliere V and Hsu T: Notch
signaling during development requires the function of awd, the
Drosophila homolog of human metastasis suppressor gene Nm23.
BMC Biol. 12:122014. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Oskarsson T, Acharyya S, Zhang XH,
Vanharanta S, Tavazoie SF, Morris PG, Downey RJ, Manova-Todorova K,
Brogi E and Massagué J: Breast cancer cells produce tenascin C as a
metastatic niche component to colonize the lungs. Nat Med.
17:867–874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Wang XY, Penalva LO, Yuan H, Linnoila RI,
Lu J, Okano H and Glazer RI: Musashi1 regulates breast tumor cell
proliferation and is a prognostic indicator of poor survival. Mol
Cancer. 9:2212010. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Reedijk M, Odorcic S, Chang L, Zhang H,
Miller N, McCready DR, Lockwood G and Egan SE: High-level
coexpression of JAG1 and NOTCH1 is observed in human breast cancer
and is associated with poor overall survival. Cancer Res.
65:8530–8537. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Tanabe H, Takayama I, Nishiyama T,
Shimazaki M, Kii I, Li M, Amizuka N, Katsube K and Kudo A:
Periostin associates with Notch1 precursor to maintain Notch1
expression under a stress condition in mouse cells. PLoS One.
5:e122342010. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Zhou M, Kawashima N, Suzuk N, Yamamoto M,
Ohnishi K, Katsube K, Tanabe H, Kudo A, Saito M and Suda H:
Periostin is a negative regulator of mineralization in the dental
pulp tissue. Odontology. 103:152–159. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Kii I, Nishiyama T, Li M, Matsumoto K,
Saito M, Amizuka N and Kudo A: Incorporation of tenascin-C into the
extracellular matrix by periostin underlies an extracellular
meshwork architecture. J Biol Chem. 285:2028–2039. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Aguirre-Ghiso JA: Models, mechanisms and
clinical evidence for cancer dormancy. Nat Rev Cancer. 7:834–846.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Aguirre Ghiso JA, Kovalski K and Ossowski
L: Tumor dormancy induced by downregulation of urokinase receptor
in human carcinoma involves integrin and MAPK signaling. J Cell
Biol. 147:89–104. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Masiero M, Minuzzo S, Pusceddu I, Moserle
L, Persano L, Agnusdei V, Tosello V, Basso G, Amadori A and
Indraccolo S: Notch3-mediated regulation of MKP-1 levels promotes
survival of T acute lymphoblastic leukemia cells. Leukemia.
25:588–598. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Enderling H, Almog N and Hlatky L: Systems
biology of tumor dormancy. Springer; New York: 2013, View Article : Google Scholar
|
|
138
|
Zhang Y, Li J, Lai XN, Jiao XQ, Xiong JP
and Xiong LX: Focus on Cdc42 in Breast Cancer: New insights, target
therapy development and non-coding RNAs. Cells. 8(pii): E1462019.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Ors-Kumoglu G, Gulce-Iz S and Biray-Avci
C: Therapeutic microRNAs in human cancer. Cytotechnology.
71:411–425. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Hayes J, Peruzzi PP and Lawler S:
MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol
Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Wu MY, Fu J, Xiao X, Wu J and Wu RC:
MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7
in breast cancer. Cancer Lett. 354:311–319. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Li XJ, Ji MH, Zhong SL, Zha QB, Xu JJ,
Zhao JH and Tang JH: MicroRNA-34a modulates chemosensitivity of
breast cancer cells to adriamycin by targeting Notch1. Arch Med
Res. 43:514–521. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Rui X, Zhao H, Xiao X, Wang L, Mo L and
Yao Y: MicroRNA-34a suppresses breast cancer cell proliferation and
invasion by targeting Notch1. Exp Ther Med. 16:4387–4392.
2018.PubMed/NCBI
|
|
144
|
Lan L, Wang Y, Pan Z, Wang B, Yue Z, Jiang
Z, Li L, Wang C and Tang H: Rhamnetin induces apoptosis in human
breast cancer cells via the miR-34a/Notch-1 signaling pathway.
Oncol Lett. 17:676–682. 2019.PubMed/NCBI
|
|
145
|
Kang L, Mao J, Tao Y, Song B, Ma W, Lu Y,
Zhao L, Li J, Yang B and Li L: MiR-34a suppresses the breast cancer
stem cell-like characteristics by downregulating Notch1 pathway.
Cancer Sci. 106:700–708. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Park EY, Chang E, Lee EJ, Lee HW, Kang HG,
Chun KH, Woo YM, Kong HK, Ko JY, Suzuki H, et al: Targeting of
miR34a-NOTCH1 axis reduced breast cancer stemness and
chemoresistance. Cancer Res. 74:7573–7582. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Suman S, Das TP and Damodaran C: Silencing
NOTCH signaling causes growth arrest in both breast cancer stem
cells and breast cancer cells. Br J Cancer. 109:2587–2596. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Heller G, Altenberger C, Steiner I,
Topakian T, Ziegler B, Tomasich E, Lang G, End-Pfützenreuter A,
Zehetmayer S, Döme B, et al: DNA methylation of microRNA-coding
genes in non-small-cell lung cancer patients. J Pathol.
245:387–398. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Li WJ, Xie XX, Bai J, Wang C, Zhao L and
Jiang DQ: Increased expression of miR-1179 inhibits breast cancer
cell metastasis by modulating Notch signaling pathway and
correlates with favorable prognosis. Eur Rev Med Pharmacol Sci.
22:8374–8382. 2018.PubMed/NCBI
|
|
150
|
Kong P, Chen L, Yu M, Tao J, Liu J, Wang
Y, Pan H, Zhou W and Wang S: miR-3178 inhibits cell proliferation
and metastasis by targeting Notch1 in triple-negative breast
cancer. Cell Death Dis. 9:10592018. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Mohammadi-Yeganeh S, Mansouri A and Paryan
M: Targeting of miR9/NOTCH1 interaction reduces metastatic behavior
in triple-negative breast cancer. Chem Biol Drug Des. 86:1185–1191.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Liang YK, Lin HY, Dou XW, Chen M, Wei XL,
Zhang YQ, Wu Y, Chen CF, Bai JW, Xiao YS, et al: MiR-221/222
promote epithelial-mesenchymal transition by targeting Notch3 in
breast cancer cell lines. NPJ Breast Cancer. 4:202018. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Forloni M, Dogra SK, Dong Y, Conte D Jr,
Ou J, Zhu LJ, Deng A, Mahalingam M, Green MR and Wajapeyee N:
miR-146a promotes the initiation and progression of melanoma by
activating Notch signaling. Elife. 3:e014602014. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Kuang W, Tan J, Duan Y, Duan J, Wang W,
Jin F, Jin Z, Yuan X and Liu Y: Cyclic stretch induced miR-146a
upregulation delays C2C12 myogenic differentiation through
inhibition of Numb. Biochem Biophys Res Commun. 378:259–263. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Marino N, Woditschka S, Reed LT, Nakayama
J, Mayer M, Wetzel M and Steeg PS: Breast cancer metastasis: Issues
for the personalization of its prevention and treatment. Am J
Pathol. 183:1084–1095. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Locatelli MA, Aftimos P, Dees EC, LoRusso
PM, Pegram MD, Awada A, Huang B, Cesari R, Jiang Y, Shaik MN, et
al: Phase I study of the gamma secretase inhibitor PF-03084014 in
combination with docetaxel in patients with advanced
triple-negative breast cancer. Oncotarget. 8:2320–2328. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Piha-Paul SA, Munster PN, Hollebecque A,
Argilés G, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A and
Gupta S: Results of a phase 1 trial combining ridaforolimus and
MK-0752 in patients with advanced solid tumours. Eur J Cancer.
51:1865–1873. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Takebe N, Nguyen D and Yang SX: Targeting
notch signaling pathway in cancer: Clinical development advances
and challenges. Pharmacol Ther. 141:140–149. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
So JY, Wahler J, Das Gupta S, Salerno DM,
Maehr H, Uskokovic M and Suh N: HES1-mediated inhibition of Notch1
signaling by a Gemini vitamin D analog leads to decreased
CD44+/CD24−/low tumor-initiating
subpopulation in basal-like breast cancer. J Steroid Biochem Mol
Biol. 148:111–121. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Krop IE, Kosh M, Fearen I, Savoie JG,
Dallob AL, Matthews CK, Stone J, Winer EP, Freedman SJ and LoRusso
PM: Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of
the novel oral Notch inhibitor MK-0752 in patients (pts) with
advanced breast cancer (BC) and other solid tumors. Ann Oncol.
22:1413–1419. 2006.
|
|
161
|
Locatelli M and Curigliano G: Notch
inhibitors and their role in the treatment of triple negative
breast cancer: Promises and failures. Curr Opin Oncol. 29:411–427.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Sanchez L, Muchene L, Lorenzo-Luaces P,
Viada C, Rodriguez PC, Alfonso S, Crombet T, Neninger E, Shkedy Z
and Lage A: Differential effects of two therapeutic cancer vaccines
on short- and long-term survival populations among patients with
advanced lung cancer. Semin Oncol. 45:52–57. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Makhoul I, Atiq M, Alwbari A and
Kieber-Emmons T: Breast cancer immunotherapy: An update. Breast
Cancer (Auckl). May 30–2018.(Epud ahead of print). doi:
10.1177/1178223418774802. View Article : Google Scholar
|
|
164
|
Gu X, Lu C, He D, Lu Y, Jin J, Liu D and
Ma X: Notch3 negatively regulates chemoresistance in breast
cancers. Tumour Biol. Oct 14–2016.(Epub ahead of print). View Article : Google Scholar
|
|
165
|
Lu X and Kang Y: Efficient acquisition of
dual metastasis organotropism to bone and lung through stable
spontaneous fusion between MDA-MB-231 variants. Proc Natl Acad Sci
USA. 106:9385–9390. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Colombo M, Raposo G and Thery C:
Biogenesis, secretion, and intercellular interactions of exosomes
and other extracellular vesicles. Annu Rev Cell Dev Biol.
30:255–289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Hoshino A, Costa-Silva B, Shen TL,
Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di
Giannatale A, Ceder S, et al: Tumour exosome integrins determine
organotropic metastasis. Nature. 527:329–335. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Lowry MC, Gallagher WM and O'Driscoll L:
The role of exosomes in breast cancer. Clin Chem. 61:1457–1465.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Schreck KC, Taylor P, Marchionni L,
Gopalakrishnan V, Bar EE, Gaiano N and Eberhart CG: The Notch
target Hes1 directly modulates Gli1 expression and Hedgehog
signaling: A potential mechanism of therapeutic resistance. Clin
Cancer Res. 16:6060–6070. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Hanna A, Metge BJ, Bailey SK, Chen D,
Chandrashekar DS, Varambally S, Samant RS and Shevde LA: Inhibition
of Hedgehog signaling reprograms the dysfunctional immune
microenvironment in breast cancer. Oncoimmunology. 8:15482412018.
View Article : Google Scholar : PubMed/NCBI
|
